Presented in partnership with BC Cancer Care The CML treatment landscape continues to evolve, with Treatment-Free Remission (TFR) becoming an increasingly important topic for patients and clinicians alike. The CML Society of Canada is proud to present this patient education and engagement event in partnership with BC Cancer Care. Together, we are committed to ensuring...Read More
English Français ⚠ Advocacy Alert Urgent: Proposed Federal Changes Could Harm CML Patients Beginning May 1, 2026, new co-payments are scheduled under the Interim Federal Health Program (IFHP), including $4 per prescription and 30% co-payments for essential medical services. For people living with CML, this is not a minor inconvenience — it is a patient...Read More
This privacy statement explains our practices governing information obtained for continuing medical education courses. Privacy policies for other activities conducted online are addressed in our general Online Privacy Policy. Our Commitment to PrivacyData CollectionData UseYour OptionsAccessData SecurityContact Us Our Commitment To PrivacyThe CML Society of Canada (hereinafter “CML”) respects the privacy of every individual who...Read More
Disclaimer – This Website does not give medical advice All of the content is for general information and educational purposes only. The information posted on this website, or by the links provided by this website, are not to be used as substitute medical advice and or recommendations. Nothing on this site should be interpreted in...Read More
Thank you for taking the time to take our survey, Generic Imatinib Mesylate – The CML Patient’s Experience. Your voice will be added to all the other voices that took the time to share their experience. Please stay tuned for updates and future plans and actions based on the results of this survey. Feel free...Read More
